Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Lowers Bar for Latest COVID Monoclonal Antibody Authorization

23 Feb 2022

• By Sarah Karlin-Smith

gymnastic bar — Lilly's new COVID-19 mab got authorized with less clinical evidence than similar mabs • Source: Alamy

Related Content

Pfizer First: Oral Antiviral Paxlovid Wins EUA As Merck’s COVID Pill Languishes At US FDA

23 Dec 2021

US FDA Authorizes Lilly’s COVID-19 mAB Combo For Lower Doses Than Tested In Phase III

11 Feb 2021

Antibody Therapies Vs. Omicron: Vir Stands Up But Regeneron And Lilly Fail

17 Dec 2021

Culture Wars Reach Labeling For COVID-19 Treatments

17 Jan 2022

Related Companies

Eli Lilly and Company

Regeneron Pharmaceuticals, Inc.

GSK plc

Pfizer Inc.

Merck & Co., Inc.

Additional Topics

United States Biologics Coronavirus COVID-19 Regulation Approvals Drug Review Drug Approval Standards BioPharmaceutical Infectious Diseases

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.